Verastem Inc. is a clinical-stage biopharmaceutical company headquartered in Needham, Massachusetts, focused on developing innovative therapies for treatment-resistant cancers. The company is advancing its proprietary drug candidates through multiple clinical trials, showcasing its potential to enhance patient outcomes and quality of life. With a dedicated approach to addressing significant unmet medical needs in oncology, Verastem presents a compelling investment opportunity for institutional investors looking to capitalize on transformative advancements in the biopharmaceutical industry. Show more

Location: 117 KENDRICK STREET, NEEDHAM, MA, UNITED STATES, 02494, Needham, MA, 02494, USA | Website: https://www.verastem.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

459.5M

52 Wk Range

$4.01 - $11.25

Previous Close

$6.10

Open

$6.06

Volume

1,254,018

Day Range

$6.01 - $6.25

Enterprise Value

434.6M

Cash

137.7M

Avg Qtr Burn

-36.22M

Insider Ownership

0.87%

Institutional Own.

88.82%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Avutometinib (VS-6766) +/- Defactinib (AVMAPKI FAKZYNJA CO-PACK) Details Low-Grade Serous Ovarian Cancer (LGSOC)	Approved Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COPIKTRA (duvelisib) Details Chronic lymphocytic leukemia, Small lymphocytic lymphoma , Cancer, Follicular lymphoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avutometinib (VS-6766), + defactinib+gemcitabine/nab-paclitaxel Details First-Line Metastatic Pancreatic Cancer (PDAC)	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GFH375 (VS-7375) Details KRAS G12D Advanced Solid Tumors	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avutometinib (VS-6766) + KRAZATI (adagrasib) Details Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avutometinib + defactinib ± KRAS G12C inhibitor Details Non-small cell lung carcinoma (NSCLC)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Avutometinib(VS-6766) (RAF/MEK Inhibitor) Details Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.